ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01648322
Recruitment Status : Completed
First Posted : July 24, 2012
Results First Posted : March 20, 2018
Last Update Posted : March 20, 2018
Sponsor:
Information provided by (Responsible Party):
Generon (Shanghai) Corporation Ltd.

Brief Summary:
This is a randomized open label dose finding study to evaluate the efficacy and safety of F-627 on women with Stage I-IV breast cancer receiving chemotherapy treatment.

Condition or disease Intervention/treatment Phase
Breast Cancer Neutropenia Drug: F-627 Drug: Neulasta® (pegfilgrastim) Phase 2

Detailed Description:

This is a randomized, multi-center, dose finding, open label, positive controlled Phase II study of the efficacy and safety of once-per-cycle of F-627 compared with Neulasta® (pegfilgrastim) in women with breast cancer who are receiving myelotoxic chemotherapy (TC: docetaxel + cyclophosphamide or TAC: docetaxel + doxorubicin + cyclophosphamide).

The primary objective of this study is to evaluate the efficacy and safety of various single cycle doses of F-627 as compared with the standard dosing of Neulasta® (pegfilgrastim) in breast cancer patients experiencing myelotoxic chemotherapy. Myelotoxicity in this study will be defined by the duration of moderate neutropenia; the number of days in which the patient has had an absolute neutrophil count (ANC) < 1.0 × 10^9/L during the first cycle of their chemotherapy treatment (each chemotherapy cycle is expected to last 21 days). This, by definition, includes grade 3 (moderate) and grade 4 (severe) neutropenia. Doses of F-627 to be tested for subjects receiving TC chemotherapy are 80 µg/kg/dose, 240 µg/kg/dose, and 320 µg/kg/dose. For subjects receiving TAC chemotherapy, only 240 µg/kg/dose and 320 µg/kg/dose are to be tested.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 232 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Study Start Date : June 2012
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: 80 µg/kg/dose of F-627
This dose of F-627 given only to subjects that are to have TC chemotherapy.
Drug: F-627
subcutaneous injection given 1 per chemotherapy.

Experimental: 240 µg/kg/dose of F-627
This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
Drug: F-627
subcutaneous injection given 1 per chemotherapy.

Experimental: 320 µg/kg/dose of F-627
This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
Drug: F-627
subcutaneous injection given 1 per chemotherapy.

Active Comparator: Neulasta® (pegfilgrastim)
Given to subjects receiving TC or TAC chemotherapy.
Drug: Neulasta® (pegfilgrastim)
Single dose injection given once per chemotherapy cycle.




Primary Outcome Measures :
  1. Duration of Moderate Neurtopenia Post First Chemotherapy Administration [ Time Frame: The first of 4, 21 Day Chemotherapy Cycles ]
    Number of days In which the patient has had an absolute neutrophil count (ANC) Level < 2.0 x 10^9/L after first cycle of chemotherapy


Secondary Outcome Measures :
  1. Duration in Days of Grade 3 and Grade 4 Neutropenia for Each of 4 Chemotherapy Cycles. [ Time Frame: Measured for each of the 4, 21 day chemotherapy cycles. ]
    Number of days In which the patient has had an ANC < 1.0 × 10^9/L (Grade 3) or ANC < .5 × 10^9/L (Grade 4) post each chemotherapy

  2. The Incidence Rate of Febrile Neutropenia [ Time Frame: Measured for each of the 4, 21 day chemotherapy cycles. ]
    The incidence rate of febrile neutropenia for each arm of the study will be recorded for 4 chemotherapy cycles. Each cycle is expected to last 21 Days.

  3. The Duration in Days of Total Grade 2 Neutropenia [ Time Frame: Measured for each of the 4, 21 day chemotherapy cycles. ]
    Number of says in which the patient has had an ANC Level ANC < 1.5 × 109/L) post each chemotherapy

  4. The Time to ANC Recovery Post Nadir [ Time Frame: Measured for each of the 4, 21 day chemotherapy cycles. ]
    The time to ANC recovery post nadir for each patient, for each of their chemotherapy cycles will be recorded; recovery for this protocol is defined as achieving an ANC ≥ 2.0 × 10^9/L after the expected ANC nadir (expected nadir is typically 4-6 days post chemotherapy administration). Each chemotherapy cycle is expected to last 21 days.

  5. The Incidence Rates of Grade 2, Grade 3, and Grade 4 Neutropenia for All Chemotherapy Cycles [ Time Frame: Measured for each of the 4, 21 day chemotherapy cycles. ]
    The incidence rate of mild, moderate and sever neutropenia for each arm of the study will be recorded for 4 chemotherapy cycles. Each cycle is expected to last 21 Days.

  6. The Depth of the ANC Nadir for All Chemotherapy Cycles [ Time Frame: Measured for each of the 4, 21 day chemotherapy cycles ]
    The depth of ANC nadir for each cycle is defined as the minimal ANC value for a subject in each chemotherapy cycle. The depth of the ANC nadir for each arm of the study will be recorded for 4 chemotherapy cycles.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Show evidence of a signed (personally or by a legally acceptable representative) and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial.
  • Females ≥ 18 years of age.
  • Diagnosed with Stage I-IV breast cancer.
  • Subject is scheduled to undergo 4 cycles of TC or TAC chemotherapy (Taxotere®, doxorubicin and cyclophosphamide, 75, 50 and 600 mg/m2, respectively).
  • ECOG Performance status of ≤ 2.
  • White Blood Cell count (WBC) ≥ 4.0 × 109/L, hemoglobin ≥ 11.5 g/dL and a platelet count ≥ 150 × 109/L.
  • Demonstrate adequate renal, hepatic function (Liver function tests (ALT, AST, alkaline phosphatase and total bilirubin)) should be less than 2.5x upper limits of normal (ULN). Serum creatinine should be less than 1.7x ULN.
  • All subjects must agree to use at least one of the following types of contraception: intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive, which has been started at least one month prior to visit one and will continue for the duration of the trial. The contraceptive patch or condom use with spermicide are also acceptable forms of contraception as long as they will be used continually throughout the duration of the trial.

Exclusion Criteria:

  • Subject is <18 or ≥ 75 years of age.
  • Disease progression has occurred while receiving a taxane regimen.
  • Subject has undergone radiation therapy within 4 weeks of enrollment.
  • Subject has undergone bone marrow or stem-cell transplantation.
  • Subject has a history of prior malignancy other than breast cancer.
  • Subjects that have used G-CSF within 6 weeks of the screening period are also excluded
  • Subject has had chemotherapy within 365 days of screening
  • Subject has documented congestive heart failure, cardiomyopathy or myocardial infarction by clinical diagnosis, ECG test, or any other relevant test.
  • History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure.
  • Unwillingness to participate in the study.
  • Any underlying medical condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or that would obscure the interpretation of adverse events.
  • Receiving other investigational drugs or biologics within 1 month or five half lives of enrollment.
  • Any condition, which can cause splenomegaly.
  • Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease.
  • ALT, AST, alkaline phosphatase > 2.5 upper limit of normal.
  • Patients with active infection, or known to be infected with chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative), or having any history of Hepatitis C.
  • Women who are pregnant or breast-feeding.
  • Patients known to be seropositive for HIV, or who have had an AIDS defining illness or a known immunodeficiency disorder.
  • Patients with a history of tuberculosis or exposure to tuberculosis. Patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated.
  • Subjects with Sickle Cell disease
  • Subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim' filgrastim, or any other component of the study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01648322


Locations
United States, Indiana
Community Hospital of Anderson
Anderson, Indiana, United States, 46011
Sponsors and Collaborators
Generon (Shanghai) Corporation Ltd.

Responsible Party: Generon (Shanghai) Corporation Ltd.
ClinicalTrials.gov Identifier: NCT01648322     History of Changes
Other Study ID Numbers: GC-627-02
First Posted: July 24, 2012    Key Record Dates
Results First Posted: March 20, 2018
Last Update Posted: March 20, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Generon (Shanghai) Corporation Ltd.:
Breast Cancer
Taxotere Chemotherapy
Neulasta
efficacy and safety
single cycle doses of F-627
pegfilgrastim

Additional relevant MeSH terms:
Breast Neoplasms
Neutropenia
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Agranulocytosis
Leukopenia
Leukocyte Disorders
Hematologic Diseases